High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia

Title
High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia
Other Titles
TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia
Author
황승용
Keywords
AML; standard chemotherapy; prognosis; topoisomerase 2; TOPOISOMERASE-II-ALPHA; DEOXYCYTIDINE KINASE; DRUG-SENSITIVITY; GENE-EXPRESSION; BLAST CELLS; CYTARABINE; RESISTANCE; IDENTIFICATION; ANTHRACYCLINES; DAUNORUBICIN
Issue Date
2012-08
Publisher
Nature Publishing Group
Citation
The British journal of cancer,Vol.107,No.1 [2012],p108-115
Abstract
BACKGROUND: Cytosine arabinoside-based chemotherapy coupled with anthracycline is currently the first-line treatment for acute myeloid leukaemia (AML), but diverse responses to the regimen constitute obstacles to successful treatment. Therefore, outcome prediction to chemotherapy at diagnosis is believed to be a critical consideration. METHODS: The mRNA expression of 12 genes closely involved in the actions of cytosine arabinoside and anthracycline was evaluated by real-time reverse transcriptase PCR (RT-PCR), in 54 diagnostic bone marrow specimens of M2-subtype AML. RESULTS: Low expression levels of ribonucleotide reductase M2 (RRM2) and high expression levels of topoisomerase 2 beta (TOP2B) were correlated with longer survival in a univariate analysis. Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy. Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P = 0.002) and overall survival (HR, 0.29; P = 0.005). CONCLUSION: Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype. British Journal of Cancer (2012) 107, 108-115. doi: 10.1038/bjc.2012.206 www.bjcancer.com Published online 24 May 2012 (C) 2012 Cancer Research UK
URI
http://search.proquest.com/docview/1022287328?accountid=11283http://hdl.handle.net/20.500.11754/41380
ISSN
0007-0920
DOI
10.1038/bjc.2012.206
Appears in Collections:
GRADUATE SCHOOL[S](대학원) > BIONANOTECHNOLOGY(바이오나노학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE